This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Health Winners & Losers: King Pharma

Stocks in this article: KG OMRI CRME

Health stocks took yet another ugly spill with the broader markets late afternoon Thursday.

The Nasdaq and Amex biotechnology indices tripped late in the trading day falling to losses of 5.3% and 4.6%, respectively, by market close. The Amex pharmaceutical index gave up a stunning 8.3% on Thursday.

One exception was King Pharmaceutical (KG), which saw share rise 27 cents, or 3.49%, to $8. Natixis Bleichroeder analyst Corey Davis upped his rating for the battered stock to buy from sell.

Meanwhile, Omrix Biopharmacueticals (OMRI) announced that a phase II study on its Fibrin Pad in mild to moderate bleeding was suspended Wednesday afternoon to investigate an incident of post-operative bleeding.

Omrix shares were on the rise a day earlier when the company said that according to interim results from a midstage trial, the Fibrin Pad was superior to Johnson & Johnson's (JNJ) Surgicel for stopping mild to moderate soft tissue bleeding during certain surgeries. Omrix Shares ultimately plummeted $6.14, or 34.5%, to $11.67, on Thursday. Cardiome (CRME) and Astellas said Thursday that they will have an "End of Review" meeting with the Food and Drug Administration on Nov. 14 regarding the application for atrial fibrillation drug Kynapid. The FDA sent the company an approvable letter -- meaning the drug could eventually be approved if certain conditions were met -- in August after an FDA advisory panel recommended in December that the agency approve Kynapid.

The companies said they also had withdrawn their application for Canadian approval and plan to refile after they have found resolution with the FDA.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs